Board of Directors

 

 

Fredrik Hübinette

Chairman of the board since 2020. Fredrik Hübinette, born 1969, is the inventor and founder of Klaria Pharma Holding, Nicoccino Holding AB and UppsalaGruppen AB. He studied at Uppsala University and has held leading positions within different biotech companies for the last 20 years. Fredrik Hübinette owns 3 886 043 shares in Klaria Pharma.

Dependent in relation to the major shareholders.

Dependent in relation to the company and company management.

 

Anders Ardstål

Member of the board since 2018. Anders Ardstål, born 1981, is an engineer and holds an MBA from Linköping University. He is Vice President Business Development at Vitrolife Sweden AB and also serves on the boards of Intellego Technologies. He is independent of both the Company and major shareholders. Anders Ardstål owns 40 000 shares in Klaria Pharma.

Independent in relation to the major shareholders.

Independent in relation to the company and company management.

 

Scott Boyer

Member of the board since 2015. Scott Boyer is a co-founder of Klaria. As Chief Scientific Officer, Scott Boyer oversees research, clinical development and regulatory affairs. Prior to joining Klaria, he was Chief Scientist at AstraZeneca with global responsibility for molecular and investigational toxicology across Astra Zeneca and he was a member of the AZ senior management team. Prior to that, he was Senior Research Scientist at Pfizer. Scott Boyer has a Ph.D from the University of Colorado, Boulder in Molecular Toxicology. He completed a NIH Fogarty International Center Postdoctoral Fellowship at the Karolinska Institute. Scott Boyer owns 731 042 shares in Klaria Pharma.

Independent in relation to the major shareholders.

Dependent in relation to the company and company management.